(665g) Rational Antimicrobial Engineering for Combating Multidrug-Resistant Pathogens | AIChE

(665g) Rational Antimicrobial Engineering for Combating Multidrug-Resistant Pathogens


Chatterjee, A. - Presenter, University of Colorado Boulder
The rapid rise of multidrug-resistant (MDR) superbugs and the declining antibiotic pipeline are serious challenges to global health. Rational design of antibiotics can accelerate development of effective therapies against MDR bacteria. In this talk, I will describe multi-pronged systems and synthetic biology based approaches being devised in our lab to rationally engineer therapeutics that can overcome antimicrobial resistance by controlling gene expression. Transcriptome studies in our lab have shown that, when exposed to antimicrobials, bacteria enter an “adaptive resistance” state by exploring multiple pathways sampling a dynamic gene regulatory space. We have developed an approach dubbed “Controlled Hindrance of Adaptation of OrganismS” or “CHAOS” to slow the evolution of antibiotic resistance by interfering with processes involved in adaptive resistance. Using CRISPR based technology, we rationally engineer library of synthetic genetic devices for multiplexed activation and inhibition of native gene expression of key essential and stress-response gene networks. Here we show that CHAOS approach leads to predominant negative epistasis with severe loss of fitness during adaptation to a range of toxins, including disinfectants and antibiotics, and eventual “slowing” down of bacteria's ability to adapt. To translate our findings into the clinical setting, we engineer antisense therapeutics that can block translation of any desired gene in a pathogen-specific manner for targeted inhibition. Using this approach we are building a Facile Accelerated Specific Therapeutic (FAST) platform for the accelerated development of peptide nucleic acid based novel antibiotics against MDR bacterial clinical isolates as well as any emergent bacterial threats. By regulating gene expression FAST can eliminate a broad range of MDR bacterial clinical isolates including methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase producing Klebsiella pneumoniae and Salmonella typhimurium, and carbapenem-resistant Escherichia coli. The CHAOS and FAST platforms presented in this talk offer novel approaches for impeding evolution of antibiotic resistance, developing new antibiotics, as well as re-sensitizing antibiotic-resistant pathogens to traditional therapies employed at the clinical setting. These approaches are also well-suited for programmable regulation of metabolic networks for bioenergy and bioengineering applications.